On June 29, the 2022 (3rd) Brand Innovation Development Conference (BIDC) under the theme of “New Dynamic, New Vigor, New Development” was successfully held online and concluded in Beijing. As a technology-enabled full service CRO, Elixir Clinical Research received the “Hero Award - the Most Innovative CRO Company in Science and Technology in 2022” because of its strong commitment and innovation in the field of digital clinical research, and its outstanding performance in using big data, artificial intelligence and other related technologies to empower all phases of clinical trials.

Elixir Clinical Research

Hero Award – the Most Innovative CRO Company in Science and Technology in 2022

Focusing on aspects such as Belt and Road, brand building, green development, science and technology innovation, 5G innovation and development, transformation and upgrading, craftsmanship, artificial intelligence, intelligent medical, the BIDC this year attracted many KOLs and industry experts. The Hero Award aims to pay tribute to many brand heroes through this award ceremony. The fact that Elixir Clinical Research was awarded such honor means that the company’s adherence to scientific and technological innovation to accelerate the research and development of new drugs since its establishment has been highly recognized.

“The 14th Five-Year Plan” is a critical period for China’s pharmaceutical industry to achieve a leap in innovation capability, industrial upgrading, and high-quality development. Multiple advanced technologies have been used to further accelerate the approval of key products, promote the simultaneous R&D and application of innovative drugs in and out of China, and facilitate rapid marketing of new drugs of high clinical value and drugs in urgent needs in clinical settings is crucial to safeguarding national health. Elixir Clinical Research, a CRO adhering to technological innovation, is committed to improving the management and operation of clinical study with digital technology, focusing on the innovation impetus of the whole process of the clinical trial, strictly following international standards, and providing pharmaceutical and medical device companies with high-quality and efficient first-class services, with the aim to accelerate the commercialization process, facilitate the launching of new drugs and benefit patients all over the world.

At the award ceremony, Mr. Liedong Xu, General Manager of Elixir Clinical Research, was invited to delivered a speech. He expressed his gratitude for the award. He emphasized that since its establishment in 2019, Elixir Clinical Research has been committed to serving the life science industry. By relying on rich project experience and the cutting-edge knowledge of its professional service team, the company provides comprehensive clinical research services with innovative digital and intelligent technologies for the whole process of new drug development, with outstanding performance in many aspects such as data-based feasibility studies, intelligent patient recruitment, intelligent database building, full lifecycle project management, remote monitoring, decentralized research model, etc. Innovation is everywhere.

Integrity, innovation, excellence, collaboration and growth are corporate values that we have been following. In the future, Elixir Clinical Research will uphold its original intention, continue to improve its scientific and technological innovation, insist on improving efficiency with technology, achieve success with quality, seek win-win results through cooperation, serve the life science industry and advance the technological development of clinical trials together with industry colleagues in the future.